Back to Search
Start Over
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235
- Source :
- Lung Cancer. 62:92-98
- Publication Year :
- 2008
- Publisher :
- Elsevier BV, 2008.
-
Abstract
- Retrospective data suggests prolonging the time to complete thoracic radiotherapy (TRT) may negatively impact tumor control and survival in limited stage small cell lung cancer (LSCLC). We examined the association between TRT duration and outcomes on a prospective phase III study.This review included 267 patients who received protocol TRT on a phase III CALGB LSCLC study assessing the addition of tamoxifen to standard chemo-radiotherapy. TRT, to a planned dose of 50Gy in 2Gy daily fractions, was initiated with the fourth chemotherapy cycle. TRT interruptions were mandated for hematologic toxicity (granulocytes1000/mm3 or platelets75,000/mm3) and esophageal toxicity (dysphagia necessitating intravenous hydration).TRT interruptionsor =3 days occurred in 115 patients (43%), most frequently during the 4th week of TRT, and did not differ between treatment arms. Hematologic toxicity and esophageal toxicity were the most frequent indications for interrupting TRT. Variables including advanced age (70 years), gender, race, or radiotherapy treatment volume did not predict for TRT interruptions. Overall survival (OS) and local tumor control did not correlate with the administration of TRT interruptions or with TRT duration.Toxicity mandated interruptions of conventional dose, once-daily, TRT may not adversely affect outcomes for patients receiving TRT concurrent with chemotherapy (cycle 4) for LSCLC. The implications for accelerated or high dose TRT regimens are not clear.
- Subjects :
- Pulmonary and Respiratory Medicine
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Antineoplastic Agents
Kaplan-Meier Estimate
Small-cell carcinoma
Article
Planned Dose
Internal medicine
medicine
Humans
Combined Modality Therapy
Chemotherapy
Radiotherapy
business.industry
Cancer
medicine.disease
Small Cell Lung Carcinoma
Surgery
Radiation therapy
Tamoxifen
Treatment Outcome
Toxicity
business
medicine.drug
Subjects
Details
- ISSN :
- 01695002
- Volume :
- 62
- Database :
- OpenAIRE
- Journal :
- Lung Cancer
- Accession number :
- edsair.doi.dedup.....4b10e0cd3f6f00dfe767589f05830b07